Sangamo Therapeutics Aktie

0,5424 EUR -0,0223 EUR -3,95 %

16:31:01

DUS

0,6351 USD -0,0070 USD -1,09 %

17:20:23

BTT

Sangamo Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.175,44 Mio. EUR

Div. Rendite0,00%

WKN936386

ISINUS8006771062

SymbolSGMO

Sangamo Therapeutics Aktien News

Sortieren:Datum Meistgelesen

07.08.25ZacksSangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

12.05.25ZacksSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

01.05.25ZacksSangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

WerbungSangamo Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.04.25BenzingaWhy Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

03.04.25BenzingaSangamo Therapeutics Stock Surges After The Bell: What's Going On?

18.03.25Benzinga8 Analysts Assess Sangamo Therapeutics: What You Need To Know

17.03.25ZacksSangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates

28.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

27.01.25BenzingaExpert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts

08.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

03.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

31.12.24Benzinga9 Analysts Have This To Say About Sangamo Therapeutics

31.12.24BenzingaSangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

31.12.24BenzingaSangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

30.12.24BusinesswireSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

19.12.24BenzingaWhy Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

19.12.24PR NewswireAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

19.12.24BusinesswireSangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

10.12.24BenzingaThe Analyst Landscape: 6 Takes On Sangamo Therapeutics

19.11.24BusinesswireSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

12.11.24ZacksSangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

12.11.24BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

04.11.24BusinesswireSangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

23.10.24Benzinga4 Analysts Have This To Say About Sangamo Therapeutics

22.10.24BenzingaWhat's Going On With Sangamo Therapeutics Shares Tuesday?

22.10.24BusinesswireSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

06.08.24BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

06.08.24BusinesswireSangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

30.07.24BusinesswireSangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

24.07.24BusinesswireSangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

09.05.24BusinesswireSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

09.05.24BusinesswireSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

02.05.24BusinesswireSangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

22.03.24BusinesswireSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

13.03.24BusinesswireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

13.03.24BusinesswireSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

12.03.24BusinesswireSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

12.02.24BusinesswireSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

06.02.24BusinesswireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

01.11.23BusinesswireSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Sangamo Therapeutics News

Sangamo Therapeutics News: auf dieser Seite finden Sie alle Sangamo Therapeutics News und Nachrichten zur Sangamo Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sangamo Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sangamo Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.